L-Carnitine
Evidence Fact Sheet
L-Carnitine is a conditionally essential amino-acid derivative that shuttles long-chain fatty acids into mitochondria for beta-oxidation. Research dose ranges are typically 2-3 g/day for body-composition studies. Reviewed evidence covers weight, exercise performance, glycemic/lipid markers, fertility and TMAO safety, including honest negatives.
Also known as: L-Carnitine · Levocarnitine · Carnitine
Overview
L-Carnitine (levocarnitine) is a conditionally essential compound synthesized endogenously from lysine and methionine and obtained from red meat and dairy. Its core mechanism is the carnitine shuttle, in which CPT1/CPT2 transport long-chain fatty acyl-CoA into mitochondria for beta-oxidation, with OCTN2 (SLC22A5) mediating cellular uptake and acetyl-group buffering of the mitochondrial acyl-CoA pool. Human research has most often explored body composition (research doses around 2-3 g/day for 12+ weeks), exercise performance, glycemic and lipid markers, and male fertility. Regulatory status: self-affirmed GRAS and a DSHEA dietary supplement in the US (with a separate prescription Levocarnitine drug pathway); an EU food supplement under Directive 2002/46/EC with ZERO authorized EFSA health claims; an ANVISA-authorized constituent in Brazil; and a GB 14880-2012 fortifier plus the lead registered weight-loss health-food ingredient in China. This page reports research findings in studied populations, not disease treatment.
Mechanism of Action
Carnitine shuttle transporting long-chain fatty acyl-CoA into mitochondria (CPT1/CPT2) for beta-oxidation · Acetyl-group buffering of the mitochondrial acyl-CoA pool · OCTN2-mediated cellular uptake; conditionally essential, endogenously synthesized from lysine + methionine
Body systems: Mitochondrial & Cellular Energy · Musculoskeletal · METABOLISM · Cardiovascular
Evidence-Based Benefits
Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — L-Carnitine is not characterized as a treatment for any disease.
Body Weight & Body Composition
Meta-analysis supported- -1.21 kgbody weight · P<0.001
- -2.08 kgfat mass · P=0.003
- 37 RCTsn=2,292
In a dose-response meta-analysis of 37 randomized trials (2,292 participants), L-carnitine supplementation produced modest reductions in body weight, BMI and fat mass, most evident in adults with overweight or obesity, with a maximum effect around 2,000 mg/day. The abstract notes no significant effect on waist circumference or body-fat percentage.
Reported effect: Weight -1.21 kg (95% CI -1.73 to -0.68; P<0.001); BMI -0.24 kg/m2 (95% CI -0.37 to -0.10; P=0.001); fat mass -2.08 kg (95% CI -3.44 to -0.72; P=0.003)
“l-carnitine supplementation provides a modest reducing effect on body weight, BMI and fat mass, especially among adults with overweight/obesity. The dose-response analysis revealed that ingestion of 2000 mg l-carnitine per day provides the maximum effect in adults.”
Source: PMID 32359762 · Talenezhad 2020 · Clin Nutr ESPEN
Weight Management (Overweight/Obese)
Meta-analysis supported- -1.129 kgbody weight · WMD
- -0.359 kg/m²BMI
An updated dose-response meta-analysis of 43 RCTs found L-carnitine lowered body weight and BMI, with benefits concentrated in overweight and obese subjects combining supplementation with lifestyle modification. Body-fat percentage and waist circumference did not change significantly, consistent with the other weight meta-analysis.
Reported effect: Body weight WMD -1.129 kg (95% CI -1.590 to -0.669); BMI -0.359 kg/m2 (95% CI -0.552 to -0.167)
“l-carnitine supplementation might have a positive effects in achieving an improved body weight and BMI especially in overweight and obese subjects.”
Source: PMID 31743774 · Askarpour 2020 · Pharmacol Res
Exercise Performance
Emerging / indexed- 3-4 gacute dose · 60-90 min pre
- 2-2.72 g/daychronic · 9-24 wk
A systematic review of 11 trials found that L-carnitine improved high-intensity exercise performance, either acutely (3-4 g ingested 60-90 minutes before testing) or chronically (2-2.72 g/day for 9-24 weeks). The same review reports no improvement in moderate-intensity exercise performance.
Effect size: this study reports the direction of the finding but does not state a specific numeric effect size, so none is given here rather than estimated.
“l-C supplementation with 3 to 4 g ingested between 60 and 90 min before testing or 2 to 2.72 g/day for 9 to 24 weeks improved high-intensity exercise performance. However, chronic or acute l-C or GPL-C supplementation did not present improvements on moderate exercise performance.”
Source: PMID 34959912 · Mielgo-Ayuso 2021 · Nutrients
Glycemic & Lipid Markers (Type 2 Diabetes)
Meta-analysis supported- -0.16%HbA1c · per 1 g/day
- -0.11 mmol/LLDL · per 1 g/day
A dose-response meta-analysis of 21 RCTs (2,041 patients with type 2 diabetes) found small reductions in serum lipids and plasma glucose per 1 g/day of L-carnitine, including LDL cholesterol (high-certainty), HbA1c (moderate) and BMI (low). The authors stress the results are small and statistical heterogeneity was high.
Reported effect: Per 1 g/day: BMI -0.37 kg/m2 (95% CI -0.59 to -0.15); HbA1c -0.16% (95% CI -0.32 to -0.01); LDL-C -0.11 mmol/L (95% CI -0.16 to -0.05)
“L-carnitine supplementation resulted in a small reduction in serum lipids and plasma glucose in patients with type 2 diabetes.”
Source: PMID 38594107 · Mirrafiei 2024 · Clin Ther
Male Fertility (Idiopathic Infertility)
Null / no benefit Meta-analysis supported- 5 studiesreported pregnancy
A meta-analysis of 8 RCTs found carnitines improved several sperm-movement parameters (total and progressive motility, morphology) but showed no demonstrable effect on clinical pregnancy rate in the five studies reporting it. This is an honest negative: laboratory semen improvements did not translate into more natural conceptions.
Effect size: this study reports the direction of the finding but does not state a specific numeric effect size, so none is given here rather than estimated.
“There was no demonstrable effect on clinical pregnancy rate in the five studies that included that outcome, although patient numbers were limited. The use of carnitines in male infertility appears to improve some sperm parameters but without evidence of an increase in the chance of natural conception.”
Source: PMID 35128424 · Khaw 2020 · Reprod Fertil
Safety · TMAO Production
RCT supported- 50 µMplasma TMAO reached
- 7.7-foldlower AUC vs carnitine (ALCAR)
A controlled pharmacokinetic trial in healthy volunteers (0.5 or 1.5 g doses) found both carnitine and acetylcarnitine had low intestinal absorption, and approximately 90% of both supplements was metabolized to TMAO, reaching plasma levels previously linked to adverse outcomes. Acetylcarnitine showed a 7.7-fold lower AUC increase than carnitine, underscoring the gut-microbiome TMAO caution noted in the safety profile.
Reported effect: ~90% of both supplements metabolized to TMAO, reaching 50 µM in plasma; acetylcarnitine AUC increase 7.7-fold lower than carnitine
“Approximately 90% of both supplements were metabolized to TMAO, reaching 50 µM in plasma, levels previously found to be associated with adverse health outcomes. The increase in area under the curve from acetylcarnitine was 7.7-fold lower than that from carnitine.”
Source: PMID 41243468 · Krims-Davis 2025 · Mol Nutr Food Res
Dosage (research context · not a recommendation)
2-3 g/day for body-composition research (>=12 weeks); 2-4 g/day with >=80 g carbohydrate co-ingestion for muscle-loading research; DSLD median marketed dose 500 mg/day; single doses best kept <=2 g for high-TMAO converters. Educational reference, not a directive.
Regulatory Status · 4 Markets
- US · FDA
- Self-affirmed GRAS + 21 CFR 107.100 optional infant-formula nutrient; dietary supplement under DSHEA (structure/function claims only). Prescription Levocarnitine (Carnitor) is an FDA-approved drug for primary carnitine deficiency / dialysis — a medical, not supplement, pathway
- EU · EFSA
- Food supplement under Directive 2002/46/EC (pre-1997 use history, no Novel Food authorization required). ZERO authorized health claims: EFSA rejected L-carnitine/ALCAR/PLC claims for lipid/fat metabolism, fatigue recovery, endurance and cognition. Only neutral nutrition-role description permitted
- CN · China
- China: GB 14880-2012 authorized nutritional fortifier plus registered SAMR health-food products for a weight-loss function (L-carnitine is the lead weight-loss / slimming health-food ingredient, with 100+ blue-hat registrations). Prescription Levocarnitine is a separate drug pathway.
- BR · ANVISA
- RDC 243/2018 / IN 28/2018 supplement framework; carnitine listed in Anexo I as an authorized constituent; no standalone authorized efficacy claim
Safety
Short-term intake <=3 g/day generally well tolerated; common effect is a fishy body/urine/breath odor from trimethylamine metabolism. TMAO caution: gut microbiota can convert high-dose oral carnitine to TMAO with inter-individual variation (Krims-Davis 2025 PMID 41243468). Contraindicated context for primary carnitine transporter disorders and beta-oxidation defects (MCAD/VLCAD) — physician evaluation needed. Drug interactions: warfarin, valproate. Prescription Levocarnitine (Carnitor) is a separate medical indication.
Related
Goals: weight-management · heart-health
Lifestyles: athletic-performance
References
PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.
- PMID 32359762 · Talenezhad 2020 · Clin Nutr ESPEN — Body Weight & Body Composition
- PMID 31743774 · Askarpour 2020 · Pharmacol Res — Weight Management (Overweight/Obese)
- PMID 34959912 · Mielgo-Ayuso 2021 · Nutrients — Exercise Performance
- PMID 38594107 · Mirrafiei 2024 · Clin Ther — Glycemic & Lipid Markers (Type 2 Diabetes)
- PMID 35128424 · Khaw 2020 · Reprod Fertil — Male Fertility (Idiopathic Infertility)
- PMID 41243468 · Krims-Davis 2025 · Mol Nutr Food Res — Safety · TMAO Production
Frequently Asked Questions
1. What is L-carnitine and what does it do in the body?
L-carnitine (levocarnitine) is a conditionally essential compound made endogenously from lysine and methionine and also obtained from red meat and dairy. Its central role is the carnitine shuttle, transporting long-chain fatty acids into mitochondria (via CPT1/CPT2) for beta-oxidation, with OCTN2 mediating cellular uptake. This page summarizes research findings, not disease treatment.
2. Does L-carnitine help with weight loss?
Meta-analyses report modest effects. Pooling 37 RCTs (n=2,292) found about -1.21 kg body weight and -2.08 kg fat mass, with the maximum effect around 2,000 mg/day, and a separate 43-RCT meta-analysis found -1.129 kg, both concentrated in overweight or obese adults. Neither found significant changes in body-fat percentage or waist circumference. These are research findings in studied populations.
3. Does L-carnitine improve athletic or exercise performance?
A systematic review of 11 trials reported improvements in high-intensity exercise performance with acute dosing (3-4 g taken 60-90 minutes before exercise) or chronic dosing (2-2.72 g/day for 9-24 weeks). The same review found no improvement in moderate-intensity exercise performance — an honest mixed result.
4. Is L-carnitine safe, and what is the TMAO concern?
Short-term intake up to about 3 g/day is generally well tolerated, with a fishy body/breath odor being a common effect. A controlled trial found roughly 90% of both carnitine and acetylcarnitine was metabolized by gut microbiota to TMAO, reaching plasma levels previously linked to adverse outcomes, which is why high single doses warrant caution in high-TMAO converters. People with primary carnitine transporter disorders or beta-oxidation defects need physician evaluation; this is evidence reporting, not clinical guidance.
Last evidence review: 2026-06-13